spartalizumab + QBM076

**Spartalizumab + QBM076** is an investigational combination therapy where spartalizumab, a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor used in cancer immunotherapy, is combined with QBM076, an orally administered small-molecule antagonist of the chemokine receptor CXCR2 primarily developed for inflammatory airway diseases such as COPD. Spartalizumab blocks PD-1 to enhance T-cell responses against tumors, while QBM076 inhibits CXCR2-mediated neutrophil migration to reduce airway inflammation. This combination as named is not documented in published clinical studies or pharmaceutical pipelines, but components are developed by Novartis.

Other names

spartalizumab plus QBM076